SFX by Ex Libris Inc.

Title:	Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus
Source:	Nature [0028-0836] Liao, H X yr:2013

Basic

Full text

Full text available via Nature

Year:

Volume:

Issue:

Start Page:

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Wei, George M M. "Antibody neutralization and escape by HIV-1." Nature 422.6929 (2003): 307-312.
description	2.	Smit, T. "Independent evolution of human immunodeficiency virus (HIV) drug resistance mutations in diverse areas of the brain in HIV-infected patients, with and without dementia, on antiretroviral treatment." Journal of virology 78.18 (2004): 10133-10148.
description	3.	Mascola JR, J R R. "Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies." Nature medicine 6.2 (2000): 207-10.
description	4.	Garber, David A A. "Prospects for an AIDS vaccine: three big questions, no easy answers." The Lancet infectious diseases 4.7 (2004): 397-413.
description	5.	Kelsoe, G. "Intraclonal generation of antibody mutants in germinal centres." Nature 354.6352: 389-392.
description	6.	Wyatt, Richard T T. "HIV vaccine design and the neutralizing antibody problem." Nature immunology 5.3 (2004): 233-6.
description	7.	Kwong, Peter D D. "HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites." Nature 420.6916 (2003): 678-82.
description	8.	Wyatt, R. "The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens." Science 280.5371 (1998): 1884-8.
description	9.	Burton, T. "Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1." Journal of virology 77.19 (2003): 10557-65.
description	10.	Groopman, L I E. "Haematologic manifestations of the human immune deficiency virus (HIV)." British journal of haematology 66.2 (1987): 251-256.
description	11.	Holmes, E C C. "On the origin and evolution of the human immunodeficiency virus (HIV)." Biological reviews of the Cambridge Philosophical Society 76.2 (2001): 239-54.
description	12.	Baba, T W W. "Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection." Nature medicine 6.2 (2000): 200-6.
description	13.	Trkola, A. "Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies." Nature medicine 11.6 (2005): 615-22.
description	14.	Njai, H F. "P04-11. Prevalence of neutralizing antibody responses in chronic clades A and D human immunodeficiency virus type 1 (HIV-1) infections." Retrovirology 6.Suppl 3 (2009).
description	15.	Mofenson, Lynne M. "Antiretroviral drugs to prevent breastfeeding HIV transmission." Antiviral therapy 15.4 (2010): 537-553.
description	16.	Montefiori, David C. "Neutralizing antibodies against HIV-1: can we elicit them with vaccines and how much do we need?" Current opinion in HIV and AIDS 4.5 (2009): 347-351.
description	17.	Portegies, P. "Guidelines for the diagnosis and management of neurological complications of HIV infection." European journal of neurology 11.5 (2004): 297-304.
description	18.	Kantor, R. "Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy." AIDS 18.11 (2004): 1503-11.
description	19.	Kumar, M. "HIV-1 Infection and its Impact on the HPA Axis, Cytokines, and Cognition." Stress 6.3 (2003): 167-172.
description	20.	Rittweger, M. "Clinical pharmacokinetics of darunavir." Clinical pharmacokinetics 46.9 (2007): 739-756.